Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04644016 · ClinicalTrials.gov registry record · Phase 2
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
A Phase 2 study of AML and MDS, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT04644016: Recruiting Phase 2 study of AML and MDS, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04644016 is a Phase 2 study of AML and MDS that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 31 participants, below the 132-participant average among 29 other AML trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04644016, a Phase 2 study of AML and MDS, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-arm study to investigate 1-year treatment related mortality (TRM) in patients with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic transplantation.
Primary Outcome
The primary objective of this study is to assess treatment related mortality (TRM) at 1 year after myeloablative cord transplant.
Conditions Studied
Interventions
- DRUG Fludarabine
- DRUG Busulfan
- DRUG Mycophenolate Mofetil
- DRUG Clofarabine
- DRUG Cyclosporine-A
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2020-11-20 |
| Est. Completion | 2026-12-20 |
| Phase | Phase 2 |
What NCT04644016 shows while recruiting
NCT04644016 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 132-participant average among 29 other AML trials with a reported enrollment target (77% lower).
The record links to 9 conditions, with AML appearing as the primary indexed condition, and to 5 interventions - of which Fludarabine is the first listed.
NCT04644016 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04644016 about?
NCT04644016 is a clinical study titled "Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders". This is a single-arm study to investigate 1-year treatment related mortality (TRM) in patients with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic transplantation.
What is the current status of trial NCT04644016?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2020-11-20. Estimated completion is 2026-12-20.
What conditions does trial NCT04644016 study?
This clinical trial studies the following conditions: AML, MDS, Hemoglobinopathies, ALL, Bone Marrow Failure.
What interventions are being tested in trial NCT04644016?
The interventions under investigation include: Fludarabine (DRUG), Busulfan (DRUG), Mycophenolate Mofetil (DRUG), Clofarabine (DRUG), Cyclosporine-A (DRUG).
Who is sponsoring clinical trial NCT04644016?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04644016 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for AML
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04644016's enrollment target sits among peer trials
31 19th of 29 higher than 11 of 29 other AML trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other AML trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease
RECRUITING · Phase 2
-
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
RECRUITING · Phase 2
-
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
RECRUITING · Phase 2
-
Cardioprotection in AML
RECRUITING · Phase 2
-
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
RECRUITING · Phase 2
-
A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI